Biotechnology company and drug delivery platform
innovator Lexaria Bioscience
(CSE: LXX) (OTC: LXRP) on Wednesday announced that work has commenced
on its largest-ever cannabinoid research program, which will also test
Lexaria-designed nanotech enhancements. According to the update, the new
program is comprised of 11 separate animal studies, each comparable in scope to
individual animal studies the company conducted during 2018. Six months ago,
Lexaria began its 2019 in vivo study design. All laboratory test articles have
been produced and exceed all required quality control thresholds, and the
project has now advanced to the implementation stage. The 2019 R&D project
is the largest undertaken in Lexaria’s history and will test DehydraTECH(TM)
delivery technology, which has already evidenced industry-leading performance,
for a variety of potential performance enhancing variations.
To view the full press release, visit http://ibn.fm/Zwvsw
About Lexaria Bioscience Corp.
Lexaria Bioscience has developed and out-licenses its
disruptive delivery technology that promotes healthier ingestion methods, lower
overall dosing and higher effectiveness of lipophilic active molecules. Lexaria
has multiple patents pending in over 40 countries around the world and has
patents granted in the USA and in Australia for utilization of its DehydraTECH(TM)
delivery technology. Lexaria’s technology provides increases in intestinal
absorption rates; more rapid delivery to the bloodstream; and important
taste-masking benefits, for orally administered bioactive molecules including
cannabinoids, vitamins, non-steroidal anti-inflammatory drugs (NSAIDs),nicotine
and other molecules. For more information, visit the company’s website at www.LexariaBioscience.com.
NOTE TO INVESTORS: The latest news and updates
relating to LXRP are available in the company’s newsroom at http://ibn.fm/LXRP
About MissionIRNewsBreaks
MissionIRNewsBreaks provide
a rapid summary of corporate news that catch the attention of MissionIR. MissionIRNewsBreaks are created by
our Team of professional journalists that keep a constant eye on the markets,
these posts are designed to inform you on the latest happenings of our clients
and other publicly traded companies on our radar. From earnings, acquisitions
and agreements to conference attendance and clinical study results, our news
breaks keep you up-to-date with the day’s top movers. MissionIR is primarily
focused on strategic communications. We have executed countless communications
programs to address the needs of companies ranging from start-ups to
established industry leaders, gaining valuable experience and the expertise
necessary to determine the most effective strategy for any given situation.
Please see full terms of use and disclaimers on the Mission
Investor Relations website applicable to all content provided by MIR, wherever
published or re-published: http://www.missionir.com/disclaimer.html
